Opus Genetics, Inc. (IRD)

NASDAQ: IRD · Real-Time Price · USD
0.9999
-0.0051 (-0.51%)
At close: May 29, 2025, 4:00 PM
0.9945
-0.0054 (-0.54%)
After-hours: May 29, 2025, 4:04 PM EDT
-0.51%
Market Cap 45.48M
Revenue (ttm) 13.65M
Net Income (ttm) -58.62M
Shares Out 45.48M
EPS (ttm) -2.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 204,035
Open 0.9980
Previous Close 1.0050
Day's Range 0.9562 - 1.0200
52-Week Range 0.6500 - 2.1800
Beta 0.27
Analysts Strong Buy
Price Target 7.00 (+600.07%)
Earnings Date May 15, 2025

About IRD

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutation... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 18
Stock Exchange NASDAQ
Ticker Symbol IRD
Full Company Profile

Financial Performance

In 2024, Opus Genetics's revenue was $10.99 million, a decrease of -42.30% compared to the previous year's $19.05 million. Losses were -$57.53 million, 476.1% more than in 2023.

Financial numbers in USD Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for IRD stock is "Strong Buy." The 12-month stock price forecast is $7.0, which is an increase of 600.07% from the latest price.

Price Target
$7.0
(600.07% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

ARVO presentation highlights 12-month results from Phase 1/2 study that support potential of OPGx-LCA5 gene therapy to restore meaningful vision Pediatric cohort of LCA5 study ongoing with initial mul...

14 days ago - GlobeNewsWire

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

RESEARCH TRIANGLE PARK, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biotechnology company developing gene therapies for the treatment of inherited retina...

17 days ago - GlobeNewsWire

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

RESEARCH TRIANGLE PARK, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inher...

23 days ago - GlobeNewsWire

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

Improvements in subjective and objective measures of efficacy observed at six months persisted for one year in patients with severe vision impairment from inherited retinal degeneration due to mutatio...

24 days ago - GlobeNewsWire

Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns

Board Timed Highly Dilutive Financing to Close on the Record Date for the Annual Meeting, Tilting the Vote and Forcing the Withdrawal of the Restore Value Slate

6 weeks ago - GlobeNewsWire

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

First pediatric patient shows encouraging early safety profile and meaningful improvement in visual function at one month A second pediatric patient was recently dosed, and the pediatric cohort is exp...

7 weeks ago - GlobeNewsWire

Opus Genetics to Participate in Upcoming Investor Conference in April

RESEARCH TRIANGLE PARK, N.C., April 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inh...

2 months ago - GlobeNewsWire

Opus Genetics Announces Financial Results for Full Year 2024

Provides update on the Company's transformation and promising portfolio of innovative gene therapy treatments for inherited retinal diseases

2 months ago - GlobeNewsWire

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Believes that Current Board's Strategic, Management and Capital Allocation Failures have Resulted in Stockholder Value Destruction

2 months ago - GlobeNewsWire

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

RESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inh...

2 months ago - GlobeNewsWire

Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

Additional approximately $21 million tied to data release for the Company's BEST1 program Additional approximately $21 million tied to data release for the Company's BEST1 program

2 months ago - GlobeNewsWire

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., March 19, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing important new therapies for the tre...

2 months ago - GlobeNewsWire

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

New Data from First Three Adult Patients in Phase 1/2 Trial with OPGx-LCA5 Showed that Subjective and Objective Signs of Efficacy Persisted for One Year New Data from First Three Adult Patients in Pha...

3 months ago - GlobeNewsWire

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

FDA Fast Track Designation granted for Phentolamine Ophthalmic Solution 0.75% as treatment of significant chronic night driving impairment in keratorefractive patients with reduced mesopic vision Enro...

3 months ago - GlobeNewsWire

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 2025 New 12-month data on the first three adult OPGx-LCA5 patients to be p...

3 months ago - GlobeNewsWire

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

Current Board's Strategic, Management, and Capital Allocation Failures Have Driven an 80% Stock Decline Over Last 22 Months

Other symbols: XBI
3 months ago - GlobeNewsWire

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

Agreement Reached on Primary Endpoint and Phase 3 Trial Design Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering FARMINGTON HILLS, Mich., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Opus Gene...

5 months ago - GlobeNewsWire